1.54
+0.13(+9.22%)
Currency In USD
| Previous Close | 1.41 |
| Open | 1.46 |
| Day High | 1.55 |
| Day Low | 1.4 |
| 52-Week High | 3.95 |
| 52-Week Low | 1.23 |
| Volume | 443,902 |
| Average Volume | 357,198 |
| Market Cap | 57.82M |
| PE | -0.64 |
| EPS | -2.39 |
| Moving Average 50 Days | 1.67 |
| Moving Average 200 Days | 1.92 |
| Change | 0.13 |
If you invested $1000 in Metagenomi, Inc. Common Stock (MGX) since IPO date, it would be worth $149.37 as of February 09, 2026 at a share price of $1.54. Whereas If you bought $1000 worth of Metagenomi, Inc. Common Stock (MGX) shares 2 years ago, it would be worth $149.37 as of February 09, 2026 at a share price of $1.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
GlobeNewswire Inc.
Jan 12, 2026 1:30 PM GMT
New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced
Metagenomi to Present at Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced